Bristol Myers Squibb (BMY) Depreciation & Amortization (CF) (2011 - 2026)

Bristol Myers Squibb (BMY) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $594.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 41.25% year-over-year to $594.0 million in Q2 2026; TTM through Jun 2026 was $3.2 billion, a 51.1% decrease from a year earlier, with the FY2025 full-year figure at $4.0 billion, down 58.22% from the prior year.
• Depreciation & Amortization (CF) was $594.0 million for Q2 2026 at Bristol Myers Squibb, roughly flat from $594.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.6 billion in Q2 2024 and troughed at $594.0 million in Q1 2026.
• A 5-year average of $1.9 billion and a median of $2.4 billion in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) advanced 6.74% in 2024 and slumped 61.06% in 2025, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $2.5 billion in 2022, then dropped by 2.26% to $2.5 billion in 2023, then slipped by 23.7% to $1.9 billion in 2024, then plunged by 48.03% to $977.0 million in 2025, then slumped by 39.2% to $594.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $594.0 million (Q2 2026), $594.0 million (Q1 2026), and $977.0 million (Q4 2025), per Business Quant data.